Patent Assignment
Reel/Frame 048888/0986
Assignment of Assignor's Interest
Recorded: 2019-04-15
Pages: 9
Assignee
IMMUNOCORE LIMITED
101 PARK DRIVE, MILTON PARK, ABINGDON, OXFORDSHIRE, OX14 4RY, UNITED KINGDOM
Covered Properties
(3)
Peptides
Application:
15/777,629 →
Publication:
US 2018/0334485
Peptides Derived from Melanoma-Associated Antigen C2 (MAGEC2) and Uses Thereof
Application:
15/777,883 →
Publication:
US 2018/0346511
Peptides Derived from Sarcoma Antigen 1 (SAGE1) and Complexes Comprising Such Peptides Bound to Mhc Molecules
Application:
15/778,179 →
Publication:
US 2018/0346536
Related Assignments
(5)
Other recorded transfers of the patents in this record — the chain of ownership.
Security Interest
Nov 6, 2020
From: IMMUNOCORE LIMITED; IMMUNOCORE LLC; IMMUNOCORE COMMERCIAL LLC
To: OXFORD FINANCE LUXEMBOURG S.À R.L., REGISTERED WITH THE LUXEMBOURG COMMERCIAL REGISTER UNDER NUMBER B243395, ACTING IN RESPECT OF ITS COMPARTMENT 1
Reel/Frame 054344/0218 →
Assignment of Assignor's Interest
Nov 30, 2020
From: IMMUNOCORE LTD.
To: IMMUNOCORE LTD.; ADAPTIMMUNE THERAPEUTICS PLC
Reel/Frame 054496/0211 →
Assignment of Assignor's Interest
Feb 2, 2021
From: IMMUNOCORE LTD.
To: IMMUNOCORE LIMITED; ADAPTIMMUNE LIMITED
Reel/Frame 055113/0241 →
Assignment of Assignor's Interest
Feb 4, 2021
From: ADAPTIMMUNE THERAPEUTICS PLC
To: ADAPTIMMUNE LIMITED
Reel/Frame 055153/0407 →
Release of Security Interest
Nov 10, 2022
From: OXFORD FINANCE LUXEMBOURG S.À R.L
To: IMMUNOCORE LIMITED; IMMUNOCORE LLC; IMMUNOCORE COMMERCIAL LLC
Reel/Frame 061916/0493 →